New study: Promising breakthrough in slowing the progression of ALS
Data demonstrates halting of disease progression in patients with ALS at 24 weeks.
Stanley Appel Coya Therapeutics Inc Amyotrophic Lateral Sclerosis Coya Therapeutics Low Dose Concept Study Evaluating Safety
Source: digitaljournal.com